(Q51954310)

18 April 2018

title

Decreased production of interleukin-2 (IL-2), IL-2 secreting cells and CD4+ cells in medication-free patients with schizophrenia. (English)

1 reference

18 April 2018

1 reference

Xiang Yang Zhang

1

1 reference

18 April 2018

Dong Feng Zhou

2

1 reference

18 April 2018

Lian Yuan Cao

3

1 reference

18 April 2018

Pei Yan Zhang

4

1 reference

18 April 2018

Gui Ying Wu

5

1 reference

18 April 2018

publication date

1 September 2002

1 reference

18 April 2018

Journal of Psychiatric Research

published in

1 reference

18 April 2018

volume

36

1 reference

18 April 2018

issue

5

1 reference

18 April 2018

page(s)

331-336

1 reference

18 April 2018

Plasma interleukin-1 beta and sleep architecture in schizophrenia and other nonaffective psychoses

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900023-7

Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900023-7

Cytokine production in drug-free and neuroleptic-treated schizophrenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900023-7

Biological significance of soluble IL-2 receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900023-7

Increased levels of CD8+ and CD4+ 45RA+ lymphocytes in schizophrenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900023-7

Cytokines production in chronic schizophrenia patients with or without paranoid behaviour.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900023-7

Cytokine profiles in drug-naive schizophrenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900023-7

Assessment of lymphocyte subsets and neutrophil leukocyte function in chronic psychiatric patients on long-term drug therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900023-7

The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900023-7

Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900023-7

Decreased interleukin-2 production in schizophrenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900023-7

Altered interleukin-2 production in schizophrenia: association between clinical state and autoantibody production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900023-7

Mitogen-stimulated interleukin-2 production in never-medicated, first-episode schizophrenic patients. The influence of age at onset and negative symptoms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900023-7

T-lymphocyte subpopulations in schizophrenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900023-7

Production of interferons and lymphokines in leukocyte cultures of patients with schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900023-7

Effects of sleep and sleep deprivation on catecholamine and interleukin-2 levels in humans: clinical implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900023-7

Decreased interleukin-2 production in Korean schizophrenic patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900023-7

Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900023-7

Cytokines and the brain: implications for clinical psychiatry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900023-7

The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900023-7

Smoking and schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900023-7

Short and long-term immunosuppressive effects of clozapine and haloperidol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900023-7

Interleukin-2 and interleukin-6 in schizophrenia and mania: Effects of neuroleptics and mood stabilizers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900023-7

In vivo immunomodulatory effects of clozapine in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900023-7

Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900023-7

T-cells and psychopathology in schizophrenia: relationship to the outcome of neuroleptic therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900023-7

Soluble IL-6 receptors in the serum and cerebrospinal fluid of paranoid schizophrenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900023-7

Increased frequency of CD8 positive gamma/delta T-lymphocytes (CD8+ gamma/delta+) in unmedicated schizophrenic patients: relation to impairment of the blood-brain barrier and HLA-DPA*02011.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900023-7

The role of immune function in schizophrenia: an overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900023-7

Increased production of interleukin-2 (IL-2) but not soluble interleukin-2 receptors (sIL-2R) in unmedicated patients with schizophrenia and schizophreniform disorder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900023-7

The immune system is a key factor in the etiology of psychosocial disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900023-7

A comprehensive macrophage-T-lymphocyte theory of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900023-7

The macrophage-T-lymphocyte theory of schizophrenia: Additional evidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900023-7

Immunosuppressive effects of clozapine and haloperidol: enhanced production of the interleukin-1 receptor antagonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900023-7

T-cell subsets in schizophrenia: a comparison between drug-naive first episode patients and chronic schizophrenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900023-7

Elevated interleukin-6 in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900023-7

Aberrant T cell-mediated immunity in untreated schizophrenic patients: deficient interleukin-2 production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900023-7

Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900023-7

Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3956%2802%2900023-7

10.1016/S0022-3956(02)00023-7

7 January 2021

Identifiers

DOI

1 reference

18 April 2018

1 reference

18 April 2018